VJHemOnc is committed to improving our service to you

IACH Focus on Leukemia 2020 | The 2020 highlights in MDS

VJHemOnc is committed to improving our service to you

Thomas Cluzeau

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the drugs in development for myelodysplastic syndromes (MDS). For lower-risk MDS, Prof. Cluzeau highlights the Phase III trial of luspatercep in patients with lower-risk MDS with ring sideroblasts as well as the Phase II trial results of imetelstat, a telomerase inhibitor, that shows good transfusion independence. Prof. Cluzeau also discusses the Phase I results of roxadustat, an oral HIF prolyl-hydroxylase inhibitor currently being evaluated in lower-risk MDS with anemia. For the treatment of higher-risk MDS, Prof. Cluzeau outlines novel agents under investigation, including APR-246 in combination with azacitidine as well as magrolimab, a CD47 inhibitor and pevonedistat, a selective NEDD8 inhibitor. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter